GLUE - Monte Rosa Therapeutics, Inc.
About Monte Rosa Therapeutics, Inc. (https://www.monterosatx.com)
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Markus Warmuth | President, Chief Executive Officer & Director | 1971 | $1,079,000 USD |
| Filip Janku | Chief Medical Officer | 1974 | $833,600 USD |
| Phil Nickson | Chief Business & Legal Officer | 1979 | $833,600 USD |
| Sharon Townson | Chief Scientific Officer | 1975 | $644,600 USD |
| Andrew Funderburk | Chief Investor Relations and Strategy Officer | – | – |
| Jennifer Champoux | Chief Operating Officer | 1972 | – |
| John C. Castle | Chief Data & Information Officer | 1971 | – |
| Magnus Walter DPHIL | Chief Technology Officer | – | – |
| Matthew Bowen | Corporate Controller & Principal Accounting Officer | 1989 | – |